Pathos AI teams up with Bristol Myers and Tempus AI to advance drug development

Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer’s Disease and Other Neurological Conditions

NEW YORK--(BUSINESS WIRE)--Oct 23, 2026-

Pathos AI Secures $237 Million in Series E Financing to Scale Agentic AI Drug Development Platform and Advance Oncology Pipeline

NEW YORK--(BUSINESS WIRE)--Oct 23, 2026-

Pathos AI teams up with Bristol Myers and Tempus AI to advance drug development

Oct 23 : Pathos AI said on Friday it had entered into a collaboration with Bristol Myers Squibb and Tempus AI to develop artificial intelligence tools for drug development in Alzheimer's disease and other neurological disorders.Pathos AI also raised $237 million in a Series E funding round led by Bristol Myer

AI drug firm Pathos raises $237 million, pushing valuation to $3 billion

AI drug firm Pathos raises $237 million, a deal that brings together a big Tempus dataset, AI analysis from Pathos, and drug development from BMS.

Pathos raises $237M at $3B valuation, signs Bristol Myers neuro partnership

AI-driven biotech Pathos AI has corralled a $237 million Series E at a $3 billion valuation, the New York-based company said on Wednesday. The large fundraise comes in below the $300 million that the biotech ...